Key Developments in Biotech:
-
Celldex Therapeutics reported that its experimental drug, barzolvolimab, did not meet expectations in a Phase 2 trial for prurigo nodularis, resulting in a drop in its stock price. The company plans to continue testing the drug for other conditions, with further data expected soon.
-
Summit Therapeutics shared updated survival data from its Phase 3 HARMONi trial of ivonescimab, a potential treatment for non-small cell lung cancer, with an FDA decision on approval anticipated by November 14.
-
In a broader context, pharmaceutical leaders are advocating against aggressive restrictions on investments in Chinese firms as policymakers consider tightened regulations.
Stay informed for more updates on these pivotal biotech news stories!
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.statnews.com/2026/07/22/biotech-news-pharma-tries-to-tamp-down-broad-china-restrictions/
